Moderna (MRNA) Tops Q2 EPS by 70c, Beats on Revenue

Moderna (NASDAQ: MRNA) reported Q2 EPS of $5.24, $0.70 better than the analyst estimate of $4.54. Revenue for the quarter came in at $4.7 billion versus the consensus estimate of $4.07 billion.

For earnings history and earnings-related data on Moderna (MRNA) click here.

You May Also Be Interested In

• Moderna (MRNA) PT Raised to $77 at Piper Sandler
• NexPoint Residential Trust (NXRT) PT Lowered to $26 at Truist Securities
• Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2